Medpage Today on MSN5mon
Cytokine Release Syndrome and Neurotoxicity After CAR T-Cell Therapy
The most frequent of these immune-mediated toxicities are cytokine release syndrome (CRS) and immune effector ... Jain ...
Healio6d
Siltuximab reduces severity of cytokine release syndrome, ICANS after CAR T-cell therapy
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...
Medscape5d
Congenital Rubella Syndrome: Progress and Future Challenges
Since 1941, when Gregg first described the triad of deafness, cataracts and cardiac disease as the classical clinical manifestations of congenital rubella syndrome (CRS), strong efforts have been ...
CURE3d
Expert Explains the Side Effects of Ordspono in R/R Follicular Lymphoma
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
Hosted on MSN12mon
New research results explore the safety of short-term cultivated CAR T cells in cancer immunotherapy
More information: Arezoo Jamali et al, Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models, EMBO Molecular Medicine (2024). DOI: 10.1038/s44321-024 ...
Medscape12d
NHL: Are Bispecific Antibodies a Safe Treatment?
TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release synd ...